seragy analytics GmbH

seragy - the Seed Biomarker Strategy Company. Our aim is to decode pathological protein aggregation and to reveal the molecular fingerprints behind proteopathies such as Alzheimer's, Parkinson’s, and ALS. These fingerprints reflect distinct disease subtypes and can correlate to disease progression and treatment response. Our proprietary SeRAS® (Seed Replication, Analysis and Subtyping) platform is the next generation of seed-based assays. SeRAS will go beyond the yes-or-no readouts to quantify protein aggregation and resolve molecular disease subtypes. Founded by scientists with decades of experience in protein aggregation research, seragy combines deep scientific knowledge with its next-generation biomarker technology to help pharmaceutical partners better understand proteopathies and develop more targeted therapeutic strategies.